Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department is aware of supply issues with Felodipine medication; and whether he has had discussions with with (a) suppliers and (b) pharmacists to minimise patient impact.

The Department is currently not aware of any supply issues affecting any strength of felodipine. While we can’t always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they arise, to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, including pharmacists, so they can advise and support their patients.